Matches in SemOpenAlex for { <https://semopenalex.org/work/W2036959351> ?p ?o ?g. }
- W2036959351 endingPage "16" @default.
- W2036959351 startingPage "7" @default.
- W2036959351 abstract "To evaluate and describe the pharmacokinetics of mycophenolic acid and its metabolite, mycophenolic acid glucuronide (MPAG), in patients with lupus nephritis, and to determine the effects of clinical parameters (urinary protein excretion as measured by the urinary protein:creatinine ratio, serum albumin level, and creatinine clearance) and demographic variables (age, race, sex) on the pharmacokinetics of total and unbound mycophenolic acid and MPAG.Pharmacokinetic analysis.University-affiliated general clinical research center.Eighteen patients with biopsy-confirmed lupus nephritis who were receiving maintenance therapy with mycophenolic acid for at least 2 weeks.Plasma and urine samples were collected for 24 hours and were assayed by high-performance liquid chromatography with ultraviolet detection.Time to maximum concentration was variable (0.5-8 hrs). Mean +/- SD fraction of unbound mycophenolic acid was 2.6 +/- 1.9%, and oral clearance (Cl/F) was about 2-fold higher (343 +/- 200 ml/min) than previously reported. Multiple regression analysis showed that Cl/F of mycophenolic acid was predicted by creatinine clearance and serum albumin level: ln Cl/F = 5.358 + 0.0092 (creatinine clearance) - 0.078 (ranked albumin), R(2)=51.1%, p=0.0195. Patients with urinary protein excretion of 1 g/day or higher had lower minimum (trough) concentrations and area under the concentration-time curve (AUC(0-12)) profiles and higher Cl/F values compared with patients with urinary protein excretion of less than 1 g/day. Patients with serum albumin levels less than 4 g/dl had higher mycophenolic acid unbound clearance and MPAG renal clearance from 0-12 hours versus those with serum albumin levels of 4 g/dl or greater. Recycling AUC (AUC(6-12)), as well as sex and age (both equally), predicted renal clearance of MPAG.Both creatinine clearance and serum albumin level were identified as primary contributors to mycophenolic acid exposure and should be considered when evaluating dosages. The results of future studies should clarify the interactions of other variables on drug exposure and treatment responses. Clinicians need to be mindful of clinical changes that occur throughout the course of lupus nephritis in order to maintain efficacy and reduce toxicity from mycophenolic acid therapy." @default.
- W2036959351 created "2016-06-24" @default.
- W2036959351 creator A5007456682 @default.
- W2036959351 creator A5007882790 @default.
- W2036959351 creator A5045125159 @default.
- W2036959351 creator A5052657277 @default.
- W2036959351 creator A5058764980 @default.
- W2036959351 creator A5059292691 @default.
- W2036959351 creator A5086851939 @default.
- W2036959351 date "2009-01-01" @default.
- W2036959351 modified "2023-09-26" @default.
- W2036959351 title "Pharmacokinetics of Mycophenolic Acid in Patients with Lupus Nephritis" @default.
- W2036959351 cites W1550111394 @default.
- W2036959351 cites W1971018450 @default.
- W2036959351 cites W1985331805 @default.
- W2036959351 cites W1994502792 @default.
- W2036959351 cites W1996853835 @default.
- W2036959351 cites W2006198853 @default.
- W2036959351 cites W2014327296 @default.
- W2036959351 cites W2016100084 @default.
- W2036959351 cites W2044634578 @default.
- W2036959351 cites W2050094658 @default.
- W2036959351 cites W2053636726 @default.
- W2036959351 cites W2058839075 @default.
- W2036959351 cites W2099244192 @default.
- W2036959351 cites W2099328600 @default.
- W2036959351 cites W2101399909 @default.
- W2036959351 cites W2116635252 @default.
- W2036959351 cites W2116823219 @default.
- W2036959351 cites W2120416054 @default.
- W2036959351 cites W2127594213 @default.
- W2036959351 cites W2132714283 @default.
- W2036959351 cites W2135881786 @default.
- W2036959351 cites W2160388191 @default.
- W2036959351 cites W3156996711 @default.
- W2036959351 doi "https://doi.org/10.1592/phco.29.1.7" @default.
- W2036959351 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2901907" @default.
- W2036959351 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19113793" @default.
- W2036959351 hasPublicationYear "2009" @default.
- W2036959351 type Work @default.
- W2036959351 sameAs 2036959351 @default.
- W2036959351 citedByCount "25" @default.
- W2036959351 countsByYear W20369593512012 @default.
- W2036959351 countsByYear W20369593512013 @default.
- W2036959351 countsByYear W20369593512014 @default.
- W2036959351 countsByYear W20369593512015 @default.
- W2036959351 countsByYear W20369593512016 @default.
- W2036959351 countsByYear W20369593512017 @default.
- W2036959351 countsByYear W20369593512018 @default.
- W2036959351 countsByYear W20369593512020 @default.
- W2036959351 countsByYear W20369593512021 @default.
- W2036959351 countsByYear W20369593512022 @default.
- W2036959351 crossrefType "journal-article" @default.
- W2036959351 hasAuthorship W2036959351A5007456682 @default.
- W2036959351 hasAuthorship W2036959351A5007882790 @default.
- W2036959351 hasAuthorship W2036959351A5045125159 @default.
- W2036959351 hasAuthorship W2036959351A5052657277 @default.
- W2036959351 hasAuthorship W2036959351A5058764980 @default.
- W2036959351 hasAuthorship W2036959351A5059292691 @default.
- W2036959351 hasAuthorship W2036959351A5086851939 @default.
- W2036959351 hasBestOaLocation W20369593512 @default.
- W2036959351 hasConcept C112705442 @default.
- W2036959351 hasConcept C126322002 @default.
- W2036959351 hasConcept C126894567 @default.
- W2036959351 hasConcept C134018914 @default.
- W2036959351 hasConcept C159641895 @default.
- W2036959351 hasConcept C2776125364 @default.
- W2036959351 hasConcept C2778033501 @default.
- W2036959351 hasConcept C2779134260 @default.
- W2036959351 hasConcept C2779912601 @default.
- W2036959351 hasConcept C2780306776 @default.
- W2036959351 hasConcept C2911091166 @default.
- W2036959351 hasConcept C71924100 @default.
- W2036959351 hasConcept C98274493 @default.
- W2036959351 hasConceptScore W2036959351C112705442 @default.
- W2036959351 hasConceptScore W2036959351C126322002 @default.
- W2036959351 hasConceptScore W2036959351C126894567 @default.
- W2036959351 hasConceptScore W2036959351C134018914 @default.
- W2036959351 hasConceptScore W2036959351C159641895 @default.
- W2036959351 hasConceptScore W2036959351C2776125364 @default.
- W2036959351 hasConceptScore W2036959351C2778033501 @default.
- W2036959351 hasConceptScore W2036959351C2779134260 @default.
- W2036959351 hasConceptScore W2036959351C2779912601 @default.
- W2036959351 hasConceptScore W2036959351C2780306776 @default.
- W2036959351 hasConceptScore W2036959351C2911091166 @default.
- W2036959351 hasConceptScore W2036959351C71924100 @default.
- W2036959351 hasConceptScore W2036959351C98274493 @default.
- W2036959351 hasIssue "1" @default.
- W2036959351 hasLocation W20369593511 @default.
- W2036959351 hasLocation W20369593512 @default.
- W2036959351 hasLocation W20369593513 @default.
- W2036959351 hasLocation W20369593514 @default.
- W2036959351 hasLocation W20369593515 @default.
- W2036959351 hasOpenAccess W2036959351 @default.
- W2036959351 hasPrimaryLocation W20369593511 @default.
- W2036959351 hasRelatedWork W1544023406 @default.
- W2036959351 hasRelatedWork W1973741567 @default.
- W2036959351 hasRelatedWork W1974378936 @default.